SLDB

7.31

3.39% 0.24

Pre-mercato: 7.32 0.01 +0.14%

Solid Biosciences Inc (SLDB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SLDB Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$7.07

Aprire:

$7.11

Volume 24 ore:

3.31M

Relative Volume:

2.85

Capitalizzazione di mercato:

$719.67M

Reddito:

$14.79M

Utile/perdita netta:

$-191.78M

Rapporto P/E:

-3.7555

EPS:

-1.9465

Flusso di cassa netto:

$-172.86M

1 W Prestazione:

+10.59%

1M Prestazione:

+5.64%

6M Prestazione:

+35.87%

1 anno Prestazione:

+58.57%

Intervallo 1D:

$7.09

$7.595

Intervallo di 1 settimana:

$6.51

$7.595

Portata 52W:

$3.79

$8.8661

Solid Biosciences Inc Stock (SLDB) Company Profile

Nome

Solid Biosciences Inc

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

617-337-4680

Indirizzo

500 RUTHERFORD AVENUE, CHARLESTOWN, MA

Dipendente

121

Cinguettio

@SolidBioDMD

Prossima data di guadagno

2026-05-21

Ultimi documenti SEC

SLDB's Discussions on Twitter

Compare SLDB vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SLDB Solid Biosciences Inc	7.31	724.59M	14.79M	-191.78M	-172.86M	-1.9465
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-20	Iniziato	Guggenheim	Buy
2025-12-04	Iniziato	Needham	Buy
2025-06-26	Iniziato	Citigroup	Buy
2025-01-08	Iniziato	Truist	Buy
2024-12-13	Iniziato	Wedbush	Outperform
2024-12-10	Iniziato	JMP Securities	Mkt Outperform
2024-07-15	Aggiornamento	JP Morgan	Neutral → Overweight
2024-06-24	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-05-31	Ripresa	Piper Sandler	Overweight
2024-03-28	Iniziato	William Blair	Outperform
2024-03-15	Iniziato	Citigroup	Buy
2024-03-14	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-12-08	Iniziato	H.C. Wainwright	Buy
2021-07-12	Iniziato	Piper Sandler	Neutral
2021-05-27	Iniziato	Jefferies	Buy
2021-03-16	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-03-09	Iniziato	Barclays	Overweight
2021-01-08	Aggiornamento	Credit Suisse	Underperform → Neutral
2020-07-28	Downgrade	SVB Leerink	Outperform → Mkt Perform
2020-05-07	Downgrade	Evercore ISI	Outperform → In-line
2019-10-11	Iniziato	Evercore ISI	Outperform
2019-08-29	Downgrade	Citigroup	Neutral → Sell
2019-08-19	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-08-16	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2019-05-14	Downgrade	Credit Suisse	Neutral → Underperform
2019-05-14	Downgrade	Goldman	Neutral → Sell
2019-02-08	Aggiornamento	Citigroup	Sell → Neutral
2019-02-08	Downgrade	SVB Leerink	Outperform → Mkt Perform
2018-11-06	Iniziato	Citigroup	Sell
2018-09-06	Iniziato	Credit Suisse	Neutral

Mostra tutto

Solid Biosciences Inc Borsa (SLDB) Ultime notizie

Jun 11, 2026

Solid Biosciences grants 77,500 options to director | SLDB Insider Trading - Stock Titan

Jun 11, 2026

Director at Solid Biosciences (NASDAQ: SLDB) granted 77,500 options - Stock Titan

Jun 11, 2026

Solid Biosciences (SLDB) director awarded 77,500 stock options at $6.61 strike - Stock Titan

Jun 11, 2026

Solid Biosciences (SLDB) director awarded 77,500 options via Perceptive Advisors - Stock Titan

Jun 11, 2026

Director at Solid Biosciences (SLDB) granted 77,500 stock options at $6.61 - Stock Titan

Jun 11, 2026

Solid Biosciences (SLDB) director receives 77,500 stock options at $6.61 exercise price - Stock Titan

Jun 11, 2026

Director at Solid Biosciences (NASDAQ: SLDB) receives 77,500 stock options grant - Stock Titan

Jun 11, 2026

Solid Biosciences (SLDB) grants director 77,500 stock options at $6.61 - Stock Titan

Jun 11, 2026

Solid Biosciences director granted 77,500 options | SLDB Insider Trading - Stock Titan

Jun 11, 2026

Jun 10, 2026

Solid Biosciences Shareholders Approve Directors and Share Increase - TipRanks

Jun 10, 2026

Solid Biosciences (NASDAQ: SLDB) shareholders approve doubling authorized stock - Stock Titan

Jun 10, 2026

Jun 08, 2026

Should I Buy SLDB (Solid Biosciences Inc.) | AI Analysis, Technical & News Insights - Kavout

Jun 08, 2026

SLDB: Gene therapy programs show robust efficacy, safety, and regulatory momentum for key indications - TradingView

Jun 08, 2026

Solid Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

Jun 08, 2026

Jun 06, 2026

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail

Jun 06, 2026

Jun 05, 2026

SLDB (NASDAQ: SLDB) supplement lists updated selling stockholders and holdings - Stock Titan

Jun 05, 2026

Solid Biosciences Rises as Investors Focus on Rare-Disease Pipeline - Bez Kabli

Jun 05, 2026

Jun 04, 2026

H.C. Wainwright raises Solid Biosciences price target on FA trial progress - Investing.com UK

Jun 04, 2026

Jun 03, 2026

SLDB Maintained by HC Wainwright & Co. -- Price Target Raised to $25 - GuruFocus

Jun 03, 2026

SLDB: Duchenne and FA gene therapy programs show strong progress, with pivotal FDA meetings ahead - TradingView

Jun 03, 2026

H.C. Wainwright raises Solid Biosciences price target on FA trial progress By Investing.com - Investing.com South Africa

Jun 03, 2026

Jun 02, 2026

Solid Biosciences And Nanomosaic Announce Co-Marketing Agreement To Advance Gene Therapy Delivery And Analytics - TradingView

Jun 02, 2026

Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics - PR Newswire

Jun 02, 2026

Jun 01, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 01, 2026

Solid Biosciences joins Jefferies Global Healthcare Conference with CEO Bo Cumbo fireside chat - Traders Union

Jun 01, 2026

Watch Solid Biosciences CEO at two June healthcare investor events - Stock Titan

Jun 01, 2026

Solid Biosciences to Participate at Upcoming Investor Conferences - The Manila Times

Jun 01, 2026

May 29, 2026

Solid Biosciences (SLDB) Edges Higher, Testing Key Resistance After Recent GainsIchimoku Cloud - The Legal Advocate

May 29, 2026

Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference - Traders Union

May 29, 2026

May 27, 2026

Solid Biosciences begins phase 3 trial for Duchenne therapy By Investing.com - Investing.com Nigeria

May 27, 2026

May 26, 2026

Solid Biosciences (SLDB) Surges 3.93% as Bullish Momentum BuildsCall Resistance - The Legal Advocate

May 26, 2026

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.

May 26, 2026

REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace

May 26, 2026

May 24, 2026